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Abstract
Renal cell carcinoma (RCC) is among the top ten most common forms of cancer and is the
most common malignancy of the kidney. Clear cell renal carcinoma (cc-RCC), the most
common type of RCC, is one of the most refractory cancers with an incidence that is on the
rise. Screening of plant extracts in search of new anti-cancer agents resulted in the discov-
ery of englerin A, a guaiane sesquiterpene with potent cytotoxicity against renal cancer cells
and a small subset of other cancer cells. Though a few cellular targets have been identified
for englerin A, it is still not clear what mechanisms account for the cytotoxicity of englerin A
in RCC, which occurs at concentrations well below those used to engage the targets previ-
ously identified. Unlike any prior study, the current study used a systems biology approach
to explore the mechanism(s) of action of englerin A. Metabolomics analyses indicated that
englerin A profoundly altered lipid metabolism by 24 h in cc-RCC cell lines and generated
significant levels of ceramides that were highly toxic to these cells. Microarray analyses
determined that englerin A induced ER stress signaling and an acute inflammatory
response, which was confirmed by quantitative PCR and Western Blot analyses. Addition-
ally, fluorescence confocal microscopy revealed that englerin A at 25 nM disrupted the mor-
phology of the ER confirming the deleterious effect of englerin A on the ER. Collectively, our
findings suggest that cc-RCC is highly sensitive to disruptions in lipid metabolism and ER
stress and that these vulnerabilities can be targeted for the treatment of cc-RCC and possi-
bly other lipid storing cancers. Furthermore, our results suggest that ceramides may be a
mediator of some of the actions of englerin A. Lastly, the acute inflammatory response
induced by englerin A may mediate anti-tumor immunity.
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Introduction
Renal cell carcinoma (RCC) is among the top ten most common forms of cancer and is the
most common malignancy of the kidney [1]. Overall, the lifetime risk for developing kidney
cancer is about 1 in 63 (1.6%) according to the American Cancer Society. Clear cell renal cell
carcinoma (cc-RCC) is the most common type of RCC with an incidence that is on the rise for
reasons that are not entirely clear [1]. The treatment options for RCC are surgery, radiation
therapy (palliative), targeted therapy (bevacizumab, sunitinib, sorafenib, everolimus, temsiroli-
mus), biological therapy (immunotherapy), and combinations of these [2,3]. Though surgical
resection can be curative in patients who suffer from localized RCC, diagnosis is frequently
made when the disease has progressed and cannot be resected. Furthermore, cc-RCC is one of
the most radio- and chemo-resistant cancers and no curative treatment is available for meta-
static cc-RCC [4]. As of 2011, the two-year survival rate for patients with metastatic disease
was reported to be under 20% despite approved targeted therapies [5]. However, the very
recent approval of two new multi-targeted agents is anticipated to improve this survival rate as
these new agents have yielded superior median overall survival in patients with metastatic
RCC compared to the previously approved single target agent, everolimus, in recent clinical
trials [6,7]. However, toxicities were associated with these new agents. Hence, there is an
urgent need to investigate novel agents that take advantage of the unique biology of RCC.
The fact that mutation in each of the RCC susceptibility genes results in the dysregulation
of at least one metabolic pathway suggests that RCC is a metabolic disease [8–10]. There is
increasing evidence supporting this notion including a recent study that found that the major-
ity of proteins dysregulated in cc-RCC, were proteins involved in glucose and lipid metabolism
[11]. Moreover, a recent landmark study conducted metabolic profiling of patient samples
with matched normal tissue and found a network of metabolic shifts associated with the gene-
sis and progression of cc-RCC tumors [12]. Though many tumors rely on increased glucose
uptake and glycolysis, few accumulate lipids to the extent of cc-RCC giving it its distinct clear
cell phenotype. The presence of extensive lipid droplets in cc-RCC suggests that cc-RCC has a
profoundly altered lipid metabolism compared to normal cells. This notion is supported by
increasing evidence including the finding of aberrant expression of fatty acid synthase, steroyl-
CoA desaturase 1 (SCD1), A:cholesterol acyl transferase, glucosylceramide synthase and sev-
eral other lipogenic genes in cc-RCC [13–15]. These findings imply that novel agents which
take advantage of this unique biology may be effective in the treatment of this chemo- and
radio-resistant cancer.
Natural products possess enormous structural and chemical diversity and are a rich source
of drugs or drug-like leads. Although the final products may not necessarily represent the
active ingredients of the natural source, the majority of all drugs in the market have their ori-
gin in nature [16,17]. Englerin A is guaiane sesquiterpene that was isolated from the Tanzanian
plant Phyllanthus engleri and has attracted much attention because of its unique structure and
cytotoxicity profile in cancer cells. Englerin A was documented to have potent cytotoxicity
preferentially against renal cancer cells [18–20] when tested against the NCI60 cell panel. Very
recently, however, a study which screened englerin A against 524 cancer cell lines from the
cancer cell line encyclopedia reported that englerin A was also cytotoxic to a small subset of
cancer cells in addition to renal cancer cells [21]. Importantly, englerin A had no toxicity
towards normal cells even at concentrations greater than 1 x 106-fold greater than the IC50 in
cancer cells sensitive to englerin A [19]. In addition to its unique structure and cytotoxicity
profile, englerin A is distinctive because it can cause cell death by multiple death mechanisms
including necrosis and apoptosis, with apoptosis occurring in the absence of caspase activation
[19,22]. The distinctive features of englerin A suggest that it has a unique mechanism of action
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and recent reports, though lacking consensus, support this notion. Englerin A has been shown
to activate protein kinase C theta (PKCθ) and was proposed to affect cell viability by promot-
ing glucose dependence while simultaneously starving cells of glucose [23]. Englerin A has also
been shown to increase cytosolic calcium levels which may play a role in the decreased phos-
phorylation and activity of the oncoprotein, EWS-FLI1, in Ewing’s sarcoma [24]. Two other
groups have reported that englerin A inhibits tumor cell growth by activating the transient
receptor potential cation channel, subfamily C, member 4 (TRPC4) ion channel, while a third
group reported that englerin A antagonized L-type calcium channels [21,25,26]. However, in
at least two of these studies, the concentration of englerin A that was required to modulate
these calcium channels was much higher than that required to kill renal carcinoma cells and
other cells sensitive to the cytotoxic effects of englerin A. For instance, the most recent study
reported that englerin A displaced a radiolabeled tool compound bound to an L-type calcium
channel in a concentration-dependent manner with a Ki of 5.7 μM. In contrast, the EC50 of
englerin A in reducing the viability or growth of most renal cancer cell lines in the NCI60 cell
panel is less than 60 nM, suggesting that modulation of L-type or TRPC calcium channels is
not required for englerin A to induce toxic effects in these cells [18–20,27]. It is still not clear
what mechanisms account for the cytotoxicity of englerin A at nanomolar levels in these cells.
We anticipate that there may be other mechanisms and targets of englerin A as natural prod-
ucts generally have multiple targets. In the current study, we chose a systems biology approach
to explore the mechanism(s) of action of englerin A at a more global level. Our findings indi-
cate that englerin A profoundly alters lipid metabolism generating ceramides, ER stress, and
a strong inflammatory response. Furthermore, our results suggest that ceramides may be a
mediator of some of the actions of englerin A.
Materials and methods
Cell culture
A498 cells were purchased from ATCC in 2012 and UO-31 cells were obtained from the NCI
in 2016. Cell lines were authenticated by morphology and by their sensitivity to englerin A
cytotoxicity. Both cell lines were maintained in RPMI medium supplemented with 10% FBS, 2
mM L-glutamine, and 100 units/ml penicillin/streptomycin (complete RPMI). All experiments
were conducted with cells of passage number less than 25.
Reagents
Englerin A was purchased from Ceriliant Corporation and Cfm Oskar Tropitzsch. C8- and
C16-ceramides and C8-ceramide-1-phosphate were obtained from Avanti Polar Lipids. Imip-
ramine hydrochloride and Cambinol were purchased from Sigma and Cayman Chemical,
respectively.
Metabolomics analysis
Cell treatment and extraction. A498 cells were plated in 100mm dishes at 0.5 x 106 and 1
x 106 cells/dish in complete RPMI for control and treated cells, respectively. The following day,
cells were refed with complete RPMI containing 0.1% DMSO or 100 nM englerin A in DMSO
with each condition being conducted in quadruplicate. Cells were incubated with vehicle or
englerin A for 24 or 48 h and then they were snap frozen with liquid nitrogen. Cell extracts
were obtained by the addition of 1 ml of ice-cold methanol:water (80:20) to each dish followed
by scraping cells into 1.7ml Eppendorf tubes and vortexing vigorously for 30 sec. A 50 ul
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aliquot of sample was removed for the picogreen DNA assay for purposes of biomass normali-
zation, and the remaining sample was kept at -80˚C until ready for metabolic analysis.
Metabolomics. Samples were analyzed on an AB SCIEX QTRAP 5500 triple quadrupole
mass spectrometer equipped with a Turbo V electrospray ionization (ESI) source, Shimadzu
LC-20A UHPLC system, and a PAL CTC autosampler. Typically, 300 μl of cells in methanol:
water (80:20) was thawed on ice and transferred to a 1.7 ml Eppendorf tube. Five μl of a cock-
tail containing 25–35 commercial stable isotope internal standards, and 5.0 μl of 57 stable
isotope internal standards that were custom-synthesized in E. coli and S. cerevisiae by meta-
bolic labeling with 13C-glucose, and 13C-bicarbonate, were added, and vortexed vigorously
for 30 sec. Macromolecules (protein, DNA, RNA, glycans, etc.) then were removed by centri-
fugation at 16,000g x 10 min at 4˚C. The supernatants containing the extracted metabolites
and internal standards were transferred to labeled cryotubes and stored at -80˚C for LC-MS/
MS analysis. LC-MS/MS analysis was performed by scheduled multiple reaction monitoring
(sMRM) under Analyst v1.6.2 software control in both negative and positive mode with
rapid polarity switching (50 ms). Nitrogen was used for curtain gas (set to 30), collision gas
(set to high), ion source gas 1 and 2 (set to 35). The source temperature was 500˚C. Spray
voltage was set to -4500 V in negative mode and 5500 V in positive mode. The values for Q1
and Q3 mass-to-charge ratios (m/z), declustering potential (DP), entrance potential (EP),
collision energy (CE), and collision cell exit potential (CXP) were determined and optimized
for each MRM for each metabolite. Ten microliters of extract was injected by PAL CTC auto-
sampler via a 10 μl stainless steel loop into a 250 mm × 2.0 mm, 4 μm polymer based NH2
HPLC column (Asahipak NH2P-40 2E, Showa Denko America, Inc., NY) held at 25˚C for
chromatographic separation. The mobile phase was solvent A: 95% water with 20 mM
(NH4)2CO3 (Sigma, Fluka Cat# 74415-250G-F), 5% acetonitrile, and 38 mM NH4OH
(Sigma, Fluka Cat# 17837-100ML), final pH 9.75; solvent B: 100% acetonitrile. Separation
was achieved using the following gradient: 0–3.5 min: 95% B, 3.6–8 min: 85% B, 8.1–13 min:
75% B, 13.5–35 min: 0% B, 36–46 min: 95% B, 46.1 min: end. The flow rate was 200 μl/min.
Pump pressures ranged from 920–2600 psi over the course of the gradient. All the samples
were kept at 4˚C during analysis. The chromatographic peaks were identified using Multi-
Quant (v3, AB Sciex), confirmed by manual inspection, and the peak areas integrated. Over
363 metabolites were detectable in all samples.
Data analysis. Metabolomic data were normalized by DNA concentration measured with
the picogreen assay then log-transformed, scaled by control standard deviations, and analyzed
by multivariate partial least squares discriminant analysis (PLSDA), principal components
analysis (PCA), t test, univariate ANOVA with pairwise comparisons and post hoc correction
for multiple hypothesis testing using Fisher’s least significant difference method in MetaboA-
nalyst [28], or the false discovery rate (FDR) method of Benjamini and Hochberg [29]. Metab-
olites with variable importance in projection (VIP) scores determined by PLSDA that were
greater than 1.5 were considered significant. Significant metabolites were grouped into path-
ways and their VIP scores summed to determine the rank-ordered significance of each bio-
chemical pathway.
Microarray analysis
Cell culture and RNA extraction. A498 cells were plated in complete RPMI onto 100
mm dishes at 0.9 x 106 cells per dish. After cells were allowed to adhere overnight, cells were
refed with complete RPMI containing 0.1% DMSO (vehicle) or 100 nM englerin A. Cells were
then incubated with englerin A or DMSO for 3, 8, and 20 h prior to isolation of RNA. Cell
extracts were prepared using 1 ml of TRI Reagent (Zymo Research, Irvine, CA) per dish. Total
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RNA was then purified from cell extracts using spin columns by Zymo Research according to
the manufacturer’s directions.
mRNA labeling and hybridization. Microarrays experiments were performed using the
Agilent platform. Total RNA was amplified and labeled using Agilent’s Low Input Quick Amp
Labeling Kit (Cat. # 5190–2306) according to the manufacturer’s recommendations. Briefly,
mRNA contained in 200 ng of total RNA was converted into cDNA using a poly-dT primer
that also contained the T7 RNA polymerase promoter sequence. Subsequently, T7 RNA poly-
merase was added to cDNA samples to amplify original mRNA molecules and to simulta-
neously incorporate cyanine-3 labeled CTP (cRNA) into the amplification product. In the next
step, labeled RNA molecules were purified using Qiagen’s RNeasy Mini Kit (Cat. # 74104).
After spectrophotometric assessment of dye incorporation and cRNA yield, samples were
stored at -80˚C until hybridization. Labeled cRNA samples (600 ng) were hybridized to Sure-
Print G3 Human Gene Expression 8x60K v2 Microarrays (Cat. # G4858A-039494) at 65˚C for
17 h using Agilent’s Gene Expression Hybridization Kit (Cat. # 5188–5242) according to the
manufacturer’s recommendations. After washes, arrays were scanned using a High Resolution
Agilent DNA Microarray Scanner System (Cat. # G2565CA) and the images saved in TIFF
format.
Data analysis. Data was extracted from images with Feature Extractor Software version
10.7.3.1 (Agilent) where background correction was also performed. Subsequently, back-
ground-corrected data was uploaded into GeneSpring GX version 11.5.1 for analysis. In this
process, data was log2 transformed, quantile normalized and base line transformed using the
median of all samples. Then, the data was filtered by flags in a way that 75% of the samples in
at least one of the treatment groups have a “detected” flag. Differentially expressed genes were
determined by analysis of the data using a moderated T test. Cutoff values of 0.01 and 1.5 were
used for p-value and fold change, respectively. GeneSpring and Ingenuity pathway analysis
software were used to perform pathway analysis and biological contextualization of the differ-
entially expressed genes. The pathway determination using Ingenuity software was conducted
by analysis of differentially expressed genes for all three time points (3, 8, 20 h), analyzed
together.
Reverse transcription and quantitative real time PCR
Culture of A498 cells and RNA extraction were carried out as described above for microaray
analysis. In independent experiments, UO-31 cells were treated with 0.1% DMSO or 40 nM
englerin A for 3 h and 8 h followed by cell harvesting and extraction of RNA as described
above.
Reverse transcription was carried out using the iScript cDNA Synthesis Kit (BioRad, Hercu-
les, CA). Each reaction contained a final volume of 20 μL including 4 μL iScript RT Supermix,
1 μg RNA, and nuclease-free water. All reverse transcription assays were conducted on the
Applied Biosystems GeneAmp PCR System 9700 (ThermoFisher Scientific, Waltham, MA).
The conditions for the reverse transcription assay were as follows: priming for 5 min at 25˚C,
reverse transcription for 30 min at 42˚C, and inactivation of reverse transcriptase for 5 min at
85˚C. Real time PCR was performed using iQ SYBR Green Supermix (BioRad). The cycling
conditions for the real time PCR for all genes except EIF4A2, were as follows: initial denatur-
ation of template at 95˚C for 3 min, followed by 45 cycles of denaturation at 95˚C for 10
sec, and primer annealing/extension at 58˚C for 30 sec. The annealing temperature for the
EIF4A2A reaction was 56.2˚C while all other conditions were the same as with other reactions.
A melt curve was also generated for each gene to confirm primer specificity and to ensure gen-
eration of only one product. All products generated were melted at 95˚C then annealed at
Englerin A disrupts lipid metabolism inducing ER stress and an acute inflammatory response in RCC
PLOS ONE | https://doi.org/10.1371/journal.pone.0172632 March 15, 2017 5 / 22
55˚C and subjected to gradual increases in temperature. The specific cycling conditions were
as follows: denaturation at 95˚C for 1 min, annealing at 55˚C for 1 min, and repeated 81 cycles
for 10 sec at 55˚C. The DNA sequences of the primers used for real time PCR were as follows:
ATF4: forward,5’-CCC CCT TCA CCT TCT TAC AA-3’, reverse,5’-AAGGGG
TGT CTT CCT CCT TT-3’; CXCL2: forward,5’-CAC TCA AGA ATG GGC AGA AA-
3’, reverse,5’-CCTCTG CAG CTG TGT CTC TC-3’; EGR1: forward,5’-TGA
CCG CAG AGT CTT TTC CT-3’,reverse,5’-TGG GTT GGT CAT GCT CAC TA-3’;
EIF4A2:forward,5’-CCG GGA GAG TGT TTG ATA TG-3’,reverse,5’-ACA CAT
CAG TTG GCA TTG TG-3’; IL6: forward,5’-ATG CAA TAA CCA CCC CTG AC-3’,
reverse,5’-GAGGTG CCC ATG CTA CAT TT-3’; PPP1R15A:5’-CAGGTC CTG
GGA GTA TCG TT-3’, reverse,5’-GGGAGG ACA CTC AGC TTC TC-3’; PPP1527:
forward,5’-GGTACC TGG GGT GTA AAG GTC-3’,reverse,5’-TACACA GGC
TTG AAC CCG AC-3’; TNFα: forward,5’-TCC TTC AGA CAC CCT CAA CC-3’,
reverse,5’-AGGCCC CAG TTT GAA TTC TT-3’. GAPDH (internalcontrol):
forward,5’-GAAGGT GAA GGT CGG AGT-3’,reverse,5’-GAA GAT GGT GAT GGG
ATT TC-3’.
Western blot analysis
A498 cells were plated in complete RPMI at 1.2 x 106 and 2.0 x 106 cells per T-75 flask for con-
trol and treated cells, respectively. After allowing cells to attach overnight, cells were treated
with 0.1% DMSO or 100 nM englerin A for 3, 8, and 24 h. Cell extracts were prepared and
Western Blot analysis was conducted as described previously [22]. Antibodies against MKK4,
p-MKK4, eIF2α, p- eIF2α, p-JNK, and B-actin were obtained from Cell Signaling Technology
(Danvers, MA) and that against JNK was obtained from Abcam (Cambridge, MA). Except for
anti-JNK (diluted 1:2000), all antibodies were diluted 1:1000. Bands were visualized using Sig-
nalFire Plus ECL enhanced chemiluminescent substrate (Pierce) and exposed to HyBlot CL
film (Denville Scientific). The film was developed with a Kodak film developer.
[3H]-thymidine incorporation assay
A498 or UO-31 cells were plated in complete RPMI at 3,500 or 2,000 cells per well of a 96-well
plate, respectively. After allowing cells to attach overnight, cells were treated with 0.1% DMSO
(vehicle), or increasing concentrations of englerin A, C8-ceramide, or C8-ceramide-1-phos-
phate and incubated for 48 h. All conditions were conducted in triplicate. Cells were pulsed
with [3H]-thymidine (1.6 μCi/well) during the last 7 h of incubation and then trypsinized and
deposited onto glass microfiber filters using the Brandel M 24 cell harvester (Gaithersburg,
MD). Incorporation of [3H]-thymidine into DNA was then determined by counting in a scin-
tillation counter (Beckman Coulter, Fullerton, CA).
Fluorescent confocal microscopy
UO-31 cells were plated in complete RPMI onto coverslips (4.9 cm2) placed in 6-well plates at
20,000 and 40,000 cells per cover slip for control and treated cells, respectively. In separate
experiments, A498 cells were plated at 65,000 cells per 2-well chamber slides. After cells were
allowed to attach overnight, cells were refed with complete RPMI containing 0.1% DMSO
(vehicle) or with englerin A at 25, 50 or 100 nM. Cells were incubated for 28.5 h with englerin
A or vehicle and then rinsed once with assay buffer (Enzo Life Sciences, Farmingdale, NY),
and fixed with 3.7% formaldehyde in assay buffer for 15 min at 37˚C. Formaldehyde solution
was prepared from a 16% formaldehyde stock (Thermo Scientific, Rockford, IL). Coverslips
were then washed 3 times with assay buffer before staining with ER-ID1 Green and Hoechst
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stain (0.8 μl of each stain per ml of assay buffer) for 25 min using the ER-ID1 Green assay kit
from Enzo Life Sciences (Farmingdale, NY). After staining, cover slips were washed 3 times
with assay buffer followed by two rinses in distilled water and then were mounted onto slides
using ProLong Diamond mounting medium (Thermo Fisher Scientific, Waltham, MA). High
resolution images were acquired with a Nikon A1R confocal microscope using a 488 nm exci-
tation laser and a 100x oil objective. Images were captured at Nyquist resolution in the XY
plane and the pinhole was adjusted to image at an optical depth of field of 0.3 microns in the Z
axis.
Results
Effects of englerin A on metabolism
Englerin A, although highly toxic to most renal cancer cell lines in the NCI60 cell panel,
requires greater than 24 h to induce significant cell death at concentrations greater than the
EC50 [22] in viability assays. This is in contrast to many chemotherapeutic agents such as
camptothecin and doxorubicin that can induce significant levels of apoptosis in less than 8 h
[30,31]. The kinetics of englerin A induced cell death indicates that multiple choreographed
events are required for cell death to take place. In line with this, we have previously demon-
strated that englerin A induces authophagy as a survival mechanism that ultimately fails and
results in cell death [22]. Taken together, our previous results suggested that englerin A
induced multiple orchestrated events leading to metabolic stress and cell death. To further
explore and study these events leading to metabolic stress and cell death, we conducted meta-
bolomics analyses given that metabolomics is the collective cellular chemistry representing the
functional interaction of genes and the environment. For these experiments, A498 cells, one of
the most sensitive renal carcinoma cell lines to englerin A cytotoxicity, were treated with vehi-
cle (0.1% DMSO) or 100 nM englerin A for 24 and 48 h. The metabolomics data set has been
deposited into the Metabolomics Workbench repository (http://dev.metabolomicsworkbench.
org:22222/data/DRCCMetadata.php?Mode=Study&StudyID=ST000465). Multivariate analy-
sis was used to identify the chemical differences between englerin A treated and control cells.
As shown in Fig 1A and 1C, these studies found that the metabolic profile of englerin A treated
cells was very distinct from vehicle treated control cells. The biochemical pathways and metab-
olites that were altered by englerin A in A498 cells were ranked and tabulated in Table 1 and
Fig 1B and 1D. For 24 h of englerin A treatment, the main finding from pathway analysis was
that changes in sphingolipids contributed to 43% of all the disturbances in metabolism associ-
ated with englerin A (Table 1). Furthermore, changes in phospholipids contributed another
23% and changes in gangliosides contributed another 22% to the metabolic disturbances asso-
ciated with englerin A treatment (Table 1). This indicates that the largest metabolic distur-
bance (88%) associated with englerin A at 24 h is due to changes in lipid metabolism. In
particular, among the top metabolites, several ceramides (4 species) and glucosylceramides (4
species) increased up to 18- and 178-fold, respectively (Fig 1B and S1 Table). On the other
hand, all sphingomyelins (10 species) decreased up to 5.5-fold. The increase in ceramides
upon treatment with englerin A is a clear sign of cell stress as ceramides are generated in
response to cell stress and mediate autophagy and cell death [32,33]. Ceramides are synthe-
sized acutely from sphingomyelins through the action of stress-induced acid and neutral
sphingomyelinases. Ceramides are also known to inhibit the respiratory complex III,
thereby inhibiting all aerobic energy production from glucose and fatty acids [34], and to
form channels in the mitochondrial membrane, activating the intrinsic arm of programmed
cell death [35]. Furthermore, ceramides are also known to promote ER stress [36,37]. In addi-
tion to the increase in ceramides, several phospholipids including phosphatidylcholine,
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Fig 1. Multivariate analysis of metabolites altered by englerin A in renal cancer cells. Multivariate analysis using partial least squares discriminant
analysis (PLSDA) clearly distinguished control and englerin A treated groups of A498 cells at both 24 h (A and B) and 48 h (C and D) durations of
treatment. Panels B and D list the top metabolites and their VIP scores and indicate how they are altered compared to control. Numbers within shaded
areas in graphs A and C represent samples within control and treated groups.
https://doi.org/10.1371/journal.pone.0172632.g001
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phosphatidylglycerol, and phosphatidylethanolamine phospholipids were decreased about 3-
to 5-fold in response to englerin A by 24 h (Fig 1B and S1 Table). The depletion in these phos-
pholipids may also result in ER stress and disrupted Golgi trafficking as previously observed
with the depletion of phosphatidylcholine [38]
Table 1. Top metabolic pathways impacted by englerin A in renal cancer cells.
Pathway Name
(24 h)
Measured
Metabolites in
the Pathway
(N)
Expected
Pathway
Proportion
(P = N/599)
Expected
Hits in
Sample of
37 (P * 37)
Observed
Hits in the
Top 37
Metabolites
Fold
Enrichment
(Obs/Exp)
Impact
(Sum
VIP
Score)
Fraction of
Impact (VIP
Score)
Explained (%
of 81.7)
Increased Decreased
Sphingolipid
Metabolism
74 0.123 4.6 17 3.7 34.9 43% 4 13
Phospholipid
Metabolism
110 0.184 6.8 11 1.6 18.9 23% 0 11
Ganglioside
Metabolism
12 0.020 0.7 4 5.4 18.0 22% 4 0
Cardiolipin
Metabolism
12 0.020 0.7 1 1.3 2.6 3% 0 1
Pyrimidine
Metabolism
26 0.043 1.6 1 0.6 2.3 3% 1 0
Purine Metabolism 34 0.057 2.1 1 0.5 1.8 2% 1 0
Cholesterol,
Cortisol, Non-
Gonadal Steroid
Metabolism
21 0.035 1.3 1 0.8 1.7 2% 1 0
Phosphate and
Pyrophosphate
Metabolism
1 0.002 0.1 1 16.2 1.6 2% 0 1
Pathway Name
(48 h)
Measured
Metabolites in
the Pathway
(N)
Expected
Pathway
Proportion
(P = N/599)
Expected
Hits in
Sample of
34 (P * 34)
Observed
Hits in the
Top 34
Metabolites
Fold
Enrichment
(Obs/Exp)
Impact
(Sum
VIP
Score)
Fraction of
Impact (VIP
Score)
Explained (%
of 82.7)
Increased Decreased
Fatty Acid
Oxidation and
Synthesis
47 0.078 2.7 14 5.2 38.7 47% 14 0
Phospholipid
Metabolism
110 0.184 6.2 5 0.8 10.8 13% 5 0
Pyrimidine
Metabolism
26 0.043 1.5 5 3.4 10.5 13% 5 0
Ganglioside
Metabolism
12 0.020 0.7 3 4.4 7.3 9% 3 0
SAM, SAH,
Methionine,
Cysteine,
Glutathione
Metabolism
21 0.035 1.2 2 1.7 4.5 5% 1 1
Purine Metabolism 34 0.057 1.9 2 1.0 4.3 5% 2 0
Eicosanoid and
Resolvin
Metabolism
22 0.037 1.2 1 0.8 2.7 3% 1 0
Pathways impacted by Englerin A were determined using MetaboAnalyst 3.0 software after measuring metabolites from A498 cells treated with 0.1%
DMSO or englerin A at 100 nM for 24 h and 48 h.
https://doi.org/10.1371/journal.pone.0172632.t001
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For 48 h of englerin A treatment, the main findings from pathway analysis was that an
increase (up to 15.5-fold) in the levels of fatty acylcarnitine, metabolites associated with lipid
oxidation, contributed to 47% of the metabolic perturbations associated with englerin A
(Table 1 and S2 Table). The reason for the increase in carnitine derivatives is likely due to
mitochondrial dysfunction and the inability to import acyl carnitines into mitochondria for
beta oxidation and ATP synthesis by mitochondrial oxidative phosphorylation. Interestingly, a
phosphatidylserine phospholipid was elevated about 7-fold (S2 Table) in response to englerin
A. Under healthy growth conditions, mitochondria receive phosphatidylserine lipids from the
ER at metabolic synapses, structured contact points in the ER called mitochondria associated
membranes. Phosphatidylserine lipids are then decarboxylated in the mitochondria to produce
phosphatidylethanolamine lipids destined for multiple metabolic fates. When mitochondria
are dysfunctional, phosphatidylserine phospholipids accumulate. Purine and pyrimidine pre-
cursors of RNA and DNA synthesis were increased at 48 h by englerin A contributing to 5%
and 13% of metabolic changes associated with englerin A, respectively (Table 1 and Fig 1D).
Specifically, among the top metabolites, AICAR, hypoxanthine, cytidine, cytidine triphosphate
and thymidine were increased suggesting a state of low energy and the inability to incorporate
purine and pyrimidine monomers into polymers of RNA and DNA (Fig 1D). Finally, among
the top metabolites, the one metabolite that was decreased was reduced glutathione (3.3-fold),
indicative of oxidative stress (Fig 1D and S2 Table). This finding is in agreement with that of a
previous report showing englerin A induced production of reactive oxygen species renal can-
cer cells [19]. Hence, 48 h of englerin A treatment resulted in mitochondrial dysfunction and
oxidative stress as well the inability to synthesize RNA and DNA. Overall, our results indicate
a profound alteration of lipid metabolism with the generation of ceramides as an initial
response to cell stress resulting in mitochondrial dysfunction and, likely, ER stress, ultimately
leading to cell death. Furthermore, our results highlight ceramides as potential key mediators
of englerin A induced cell stress and cell death.
Englerin A induces ER stress and an unfolded protein and inflammatory
response
The key finding of the generation of ceramides by englerin A would suggest specific stress sig-
naling associated with ceramides. For instance, ceramides are known to induce ER stress
resulting in the unfolded protein response as well as to participate in autophagic response sig-
naling [39]. Hence, to extend and further confirm our findings from metabolomic analyses we
conducted microarray analysis using the Agilent platform (SurePrint G3 Human Gene Expres-
sion 8x60K v2 Microarrays). For this study, A498 cells were treated with 100 nM englerin A or
vehicle (0.1% DMSO) for 3, 8, and 20 h to examine early, intermediate, and late events. The
microarray data set has been deposited into the GEO repository (http://www.ncbi.nlm.nih.
gov/geo/query/acc.cgi?acc=GSE86047). The list of differentially expressed genes at the three
different durations of englerin A treatment relative to control are presented in S3 Table. Both
GeneSpring and Ingenuity software were used for pathway analysis. The top most significant
pathways modulated by englerin A are listed in Table 2. The pathways that are labeled with an
asterisk () in Table 2 are those that were determined by both GeneSpring and Ingenuity soft-
ware. For the most part, the pathways determined by each of the software were either related
pathways or the same pathways. The top pathway modulated by englerin A was ErbB1 down-
stream signaling. The ErbB receptors signal through Akt, MAPK, and other pathways to regu-
late cell proliferation, migration, differentiation, apoptosis, and cell motility. Previously, we
identified that englerin A inhibited the phosphorylation of both Akt and Erk [22], in agree-
ment with modulation of downstream ErbB1 signaling. Both pathway analysis software
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identified the AP1 transcription factor network to be modulated by englerin A at 3h. This net-
work also includes the ATF2 transcription factor which is upregulated by englerin A at 3 h.
Members of this transcription factor network are involved in cell stress signaling and are acti-
vated by stress kinases such as JNK and p38 [40,41]. This stress signaling is likely due to ER
stress as PERK regulated gene expression is induced by englerin A within 3 h. PERK is a type I
membrane protein located in the endoplasmic reticulum, where it is induced by ER stress
caused by misfolded proteins [42]. Ceramides are an established ER stressor that can lead to an
unfolded protein response [39,43]. Though not among the top pathways regulated by englerin
A at the gene level, pathway analysis by GeneSpring did identify ceramide signaling among
pathways modulated by englerin A (P = 0.0057, 5/45 genes regulated). This finding is in
Table 2. Top cell signaling pathways regulated by englerin A in renal cancer cells.
Pathway P-Value Number of Genes Regulated in
Pathway
Number of Pathway Genes in
Experiment
3 h of EA treatment
ERbB1 downstream signaling 6.76 x 10−5 15 168
AP-1 transcription factor network* 1.31 x 10−4 5 20
TLR signaling* 1.35 x 10−4 7 42
ATF2 transcription factor network 1.39 x 10−4 8 57
PDGFR-B signaling 2.71 x 10−4 13 150
TGF-ßR signaling 2.97 x 10−4 12 132
Golgi associated vesicle biogenesis 3.32 x 10−4 4 13
Nectin adhesion 4.76 x 10−4 13 159
TNF signaling* 6.66 x 10−4 3 7
PERK regulated gene expression 6.66 x 10−4 3 7
8 h of EA treatment
ERbB1 downstream signaling 4.00 x 10–5 19 168
ATF2 transcription factor network 6.13 x 10−5 10 57
PDGFR-B signaling 9.72 x 10−5 17 150
IL-12 mediated signaling 1.13 x 10−4 9 49
Amb2 integrin signaling 1.2 x 10−4 6 21
Nectin adhesion 1.98 x 10−4 17 159
Nuclear ERß network 2.61 x 10−4 4 9
20 h of EA treatment
RIG-I/MDA5 mediated* induction of IFN-alpha/beta
pathways
3.46 x 10−6 6 31
TLR signaling 2.17 x 10−5 6 42
IL-12 signaling 5.34 X 10−5 6 49
Cytokine Signaling* 7.09 x 10−5 4 18
ATF2 transcription factor network 1.14 x 10−4 6 57
IL-23 signaling 1.99 x 10−4 3 9
Cytokine-cytokine receptor interaction* 2.38 x 10−4 10 185
RIG1-like receptor signaling 4.04 x 10–4 4 26
Microarrays experiments were performed using Agilent’s platform. Probes that achieved a significance of P = 0.01 or less in the ANOVA analysis with
Benjamin-Hochberg correction were subjected to pathway analysis by GeneSpring and Ingenuity Pathway Analysis software. A fold change of 1.5 or
greater was used in these analyses. For pathway analysis using Ingenuity software, the differentially expressed genes for all three time points (3, 8, 20 h)
were analyzed simultaneously.
* Pathways labeled with an asterisk (*) are those determined by both Ingenuity and GeneSpring software.
https://doi.org/10.1371/journal.pone.0172632.t002
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agreement with our metabolomics data suggesting ceramides as a mediator of englerin A
action. Several additional findings support this notion. For instance, englerin A upregulated
TNF expression by 15-fold (S3 Table) thereby regulating TNF signaling, a pathway also known
to be modulated by ceramides [44]. Ceramides are reported to result in cell death via interac-
tion with members of the TNF superfamily of receptors[44,45]. Ceramide promoted ER stress
is known to activate Toll like receptor (TLR) signaling and inflammation [46]. In agreement
with this, pathway analysis by both GeneSpring and Ingenuity determined that englerin A
induced TLR signaling by 3 h (Table 2). Collectively, these results suggest that ceramides gen-
erated in response to englerin A induce ER stress resulting in an unfolded protein response
and inflammatory signaling by TNF and TLR.
Because of their association with Jun, Fos, ATF3 and other members, additional pathways
that may be modulated by engerin A at 3 h also included the PDGF and TGF-ß signaling path-
ways (Table 2). Importantly, both of these pathways signal through ERK1/2 which is inhibited
by engerin A [22]. Lastly, englerin A was determined to modulate nectin adhesion as well as
Golgi-associated vesicle biogenesis, the later which is required for cytokine secretion and is
consistent with TLR signaling.
As shown in Table 2, several of the pathways regulated by englerin A at 8 h include those
also modulated at 3 h. Additional pathways potentially affected by englerin A at 8 h include IL-
12 and Amb2 integrin signaling, as well as signaling associated with the nuclear ERß network.
Englerin A induces the expression of several interleukin genes and their receptors thus affect-
ing their associated signaling including that of IL-12 (S3 Table). Members of the amb2 integrin
pathway include NFκB, AKT, TNF and IL-6, all of which are modulated by englerin A at the
gene or protein level [22] (S3 Table). Lastly, The ERß receptor is known to interact with other
transcription factors such as AP1 through transcription factor cross talk. Hence modulating
the expression of members of the AP1 network by englerin A may regulate ERß signaling [47].
Pathway analysis indicated that at 20 h, englerin A clearly induced an inflammatory
response akin to the response to pathogens through pattern recognition receptors belonging to
the RIG-1 like family (Table 2). These responses included signaling by interferon α/ß as well as
signaling by inflammatory interleukins including IL-23 and IL-12. Furthermore, the expres-
sion of several inflammatory chemokines including CCL4, CXCL2, and CCL20 were also
induced by englerin A by up to 34-fold (S3 Table). Although the expression of several interleu-
kin genes were elevated prior to 20 h, interferon signaling only became apparent at 20 h sug-
gesting a gradual build to an inflammatory response culminating in interferon signaling. In
summary, gene expression profiling and pathway analysis have revealed that englerin A
induced ER stress signaling, also known as the unfolded protein response, likely due to the
generation of ceramides as well as to the depletion of certain phospholipids. This response
involved both PERK and the AP1 transcription factor network, the latter, which is activated by
the stress kinase, JNK. Secondly, englerin A induced an inflammatory response involving sig-
naling by TNF, interleukins, as well as that by interferon α/ß. These findings are in agreement
with different lines of research revealing that pathways activated by ER stress such as the
unfolded protein response induce sterile inflammation in various cells [46,48].
In order to confirm our findings from microarray analysis regarding englerin A induced
ER stress signaling and inflammation we conducted quantitative PCR analyses using both
A498 and UO-31 renal carcinoma cell lines. In these experiments, A498 and UO-31 cells were
treated for 3–20 h with 100 nM and 40 nM englerin A, respectively. Control cells were treated
with 0.1% DMSO. The mRNA levels of several genes associated with ER stress-induced
unfolded protein response signaling including ATF4, EGR1, EIF4A2, and PPP1R1A were ana-
lyzed. EIF4A2 which is involved in EIF2 and eIF4/p70S6K signaling in the initiation of transla-
tion [49] was upregulated over 2-fold in both A498 and UO-31 cells, in agreement with
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microarray results (Table 3). Activating transcription factor 4 (ATF4) is a component of the
PERK arm of ER stress signaling that drives the expression of CHOP and GADD34, also
known as PPP1R15A. The expression of both ATF4 (up to 3.3-fold) and GADD34/PPP1R15A
(up to 11.3-fold) were upregulated by englerin A in both cell lines at 3 h and at 8 h. Further-
more, the expression of EGR1 which encodes a transcription factor regulated by PERK and
plays a crucial role in stress induced cytokine production [50] was increased in both A498 and
UO-31 cells by up to about 32-fold, with the greatest increase occurring at 3 h consistent with
microarray results. Real time RT-PCR analysis of inflammatory cytokines and chemokines
including TNFα, IL-6, and CXCL2 revealed dramatic increases (up to 56.7-fold) in their
expression in response to englerin A in both A498 and UO-31 (Table 3). Collectively, the
results of the quantitative RT-PCR experiments verified the results of the microarray analysis
and indicated that englerin A induced ER stress signaling and an inflammatory response.
In order to confirm at the phosphoprotein level that englerin A induced an unfolded pro-
tein and inflammatory response, Western Blot analysis using phospho-specific antibodies was
conducted to examine signaling pathways characteristic of these responses. One of the hall-
marks and earliest events following ER stress is the phosphorylation of eIF2α by PERK, the
major protein responsible for attenuation of mRNA translation. Western analysis revealed that
phosphorylation of eIF2α was induced by englerin A (100 nM) in A498 cells at 3 h with the
greatest level of phosphorylation occurring at 24 h (Fig 2A). We also examined the phosphory-
lation of the stress kinase, JNK, and its upstream kinase MKK4/7 which are activated by the
ER stress sensor, inositol requiring enzyme 1, IRE1α. Furthermore, activation of JNK is a key
step in the induction of inflammatory cytokines via AP1 [46,51]. Western blot analysis con-
firmed that both MKK4/7 and JNK were activated by englerin A by 3 h (Fig 2A). Collectively,
these findings support results from both microarray and quantitative PCR experiments and
confirm that englerin A induces an unfolded protein response as well as an inflammatory
response.
Englerin A disrupts ER morphology
Since englerin A induces ER stress signaling we sought to determine whether englerin A, like
some ER stress inducing agents, could disrupt the morphology of the ER further confirming
the deleterious effect of englerin A on the ER. In these experiments, UO-31 cells were treated
with 0.1% DMSO or englerin A (25 nM) for 28.5 h and then stained with ER-ID1 Green and
Table 3. Real time PCR confirms upregulation of genes associated with the unfolded protein response and inflammation.
A498 UO-31
Gene Fold Change (microarray/qPCR) Fold Change (qPCR)
3 h 8 h 20 h 3 h 8 h
ATF4 1.9/2.2 1.7/2.2 1.3/1.3 1.5 3.3
EGR1 24.4/31.7 11.3/18.8 2.8/3.7 15.2 9.4
EIF4A2 2.6/2.1 2.0/2.3 1.3/1.8 2.2 2.2
PPP1R15A 7.8/9.6 7.6/11.3 3.4/4.5 6.0 8.3
TNFα 15.6/23.4 22.8/56.7 10.5/18.6 1.0 14.3
IL-6 9.5/12.2 5.4/8.7 3.1/5.1 0.8 8.8
CXCL2 10.5/13.6 8.2/11.3 6.5/7.9 0.8 2.5
Reverse transcription and real time PCR was conducted for select genes using RNA isolated from A498 and UO-31 renal carcinoma cells treated with 0.1%
DMSO (vehicle) or englerin A at 40 nM (UO-31) or 100 nM for the indicated times. The fold change in select genes obtained from both microarray and real
time PCR experiments are presented as indicated.
https://doi.org/10.1371/journal.pone.0172632.t003
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Fig 2. Englerin A induces ER stress signaling and morphological changes in the ER. Western blot analysis (A) was performed using
protein extracts obtained from A498 cells treated with 0.1% DMSO (vehicle) or 100 nM englerin A for the indicated times. ER morphology (B)
was imaged by fluorescence confocal microscopy of UO-31 cells that were treated with vehicle or 25 nM englerin A for 28.5h followed by
staining of cells with ER-ID® Green and Hoechst stain. Arrows show areas of the ER with disrupted fine tubular network.
https://doi.org/10.1371/journal.pone.0172632.g002
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Hoechst stain followed by imaging by fluorescent confocal microscopy. As shown in Fig 2B,
control cells treated with 0.1% DMSO display a fine tubular network characteristic of an
unstressed ER whereas cells treated with englerin A display disruption of this network and the
formation of sack-like cisternae with increased staining typical of a stressed ER [52,53]. Similar
results were observed in A498 cells treated with englerin A in separate independent experi-
ments (data not shown). Our finding that englerin A disrupts ER morphology is consistent
with our metabolomics results revealing that englerin A generates ceramides and depletes
phosphatidylcholine and other phospholipids (at 24 h) as well as with our microarray and real
time PCR results demonstrating ER stress induced unfolded protein response signaling. Thus,
englerin A not only induces ER stress signaling but also disrupts the normal morphology of
the ER.
Ceramides are toxic to A498 and UO-31 renal carcinoma cells
The induction of ceramides by different stimuli is known to cause ER stress and cell death
[39,43]. In order to confirm that A498 and UO-31 cells which are two of the most sensitive cell
lines to the cytotoxicity of englerin A (IC50 < 20 nM) (Fig 3A) [18,22] are also sensitive to the
cytotoxicity of ceramides, proliferation assays were conducted. For these experiments, A498
and UO-31 cells were treated with increasing concentrations of englerin A or C8-ceramide for
48 h followed by measurement of cell proliferation using [3H]-thymidine incorporation. It is
important to note that, unlike endogenously induced ceramides, exogenously added ceramides
have difficulty reaching their targets as they do not penetrate cells well and are subject to stick-
ing to inanimate surfaces thus necessitating the use of micro molar levels in various assays to
observe an effect. As shown in Fig 3B, both A498 and UO-31 cells were sensitive to the cyto-
toxicity of C8-ceramide with an IC50 of 4 μM and 7 μM, respectively. Interestingly, C8-cerami-
de1-phosphate was also toxic to A498 cells with an IC50 less than 7.5 μM (data not shown). On
the other hand, C16-ceramide which does not penetrate cells did not have any effect on cell
proliferation (data not shown). Our results indicate that both A498 and UO-31 cells are sensi-
tive to the cytotoxicity of ceramides and that ceramides likely mediate some of the effects of
englerin A, especially relating to ER stress and inflammation. Attempts to block the generation
of ceramides with various inhibitors of acid and neutral sphingomyelinases, the enzymes
Fig 3. Renal cancer cells are highly sensitive to growth inhibition by englerin A and ceramide. [3H]-Thymidine incorporation was measured in A498
and UO-31 cells treated with 0.1% DMSO (control) or increasing concentrations of englerin A (A) or C8-ceramide (B) for 48 h.
https://doi.org/10.1371/journal.pone.0172632.g003
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activated by various stress stimuli to generate ceramides, were uninformative due to the inher-
ent toxicity of these inhibitors to A498 and UO-31 cells (data not shown). Hence, future stud-
ies will aim to elucidate the mechanism by which ceramides are generated in response to
engerin A and delineate which actions of englerin A ceramides may mediate.
Discussion
In the current study, we have found that englerin A profoundly altered lipid metabolism in
A498 cc-RCC cells and generated a significant level of ceramides. We further found that
engerin A induced ER stress/unfolded protein response signaling in both A498 and UO-31
cells. The induction of ER stress was confirmed by confocal microscopy imaging revealing that
englerin A altered the normal morphology of the ER. Lastly, our results indicated that englerin
A induced a significant inflammatory response with the induction of signaling by interferon
α/ß as well as signaling by inflammatory interleukins and TNF.
Though many tumors rely on increased glucose uptake and glycolysis, few accumulate lip-
ids to the extent of cc-RCC, giving it its distinct clear cell phenotype. The presence of exten-
sive lipid droplets in cc-RCC suggests profoundly altered lipid metabolism compared to
normal cells. In fact, there is increasing evidence of altered lipid metabolism in cc-RCC
including aberrant expression of fatty acid synthase, steroyl-CoA desaturase 1 (SCD1), A:
cholesterol acyl transferase, glucosylceramide synthase and several other lipogenic genes
[13–15]. These findings suggest that this aberrant lipid metabolism is necessary for the sur-
vival of cc-RCC and possibly for other fat storing tumor cells. Therefore, targeting this aber-
rant lipid metabolism in such cells may be a strategy to selectively kill them. Evidence
supporting this notion is mounting and further reveals that perturbations of lipid metabo-
lism in cc-RCC results in ER stress and cell death. For example, one study targeted SCD1,
overexpressed in cc-RCC, using a novel inhibitor and showed that inhibition or genetic
knockdown of SCD1 resulted in ER stress and apoptosis in vitro and in vivo [14]. Moreover,
a recent study clearly showed a connection between lipid storage, ER homeostasis, and via-
bility in cc-RCC [54]. In particular, this study demonstrated the presence of highly elevated
levels of the lipid droplet coat protein, PLIN2, in cc-RCC that functioned to enable lipid stor-
age. In addition, it was found that increased PLIN2 expression and lipid storage were driven
by HIF2 alpha and were required to maintain ER homeostasis and cell viability. Suppression
of PLIN2 expression resulted in reduced lipid storage, ER stress, and cell death. These studies
revealed lipid metabolism and ER stress as a targetable vulnerability in the most common
form of RCC. Based on the findings of these and similar studies, it appears that englerin A,
by altering lipid metabolism induces ER stress and cell death. However, since the metabolo-
mics experiments in the current study were conducted using A498 cells only, it may not be
possible to extrapolate to other cc-RCC cells in regards to the disruption of lipid metabolism
by englerin A culminating in ER stress and cell death. Notably, according to the results of
cytotoxicity profiling of englerin A in over 500 cancer cell lines, [21] the cancer cell types
most sensitive to englerin A, in addition to renal cancer cells, included those of bone, central
nervous system, and liver, all of which are known to store relatively large amounts of lipids
[55–59]. This finding is in line with our results and further supports lipid metabolism and
ER stress as a targetable vulnerability in lipid storing tumor cells.
In altering lipid metabolism, englerin A significantly increases the levels of ceramides,
likely by activating sphingomyelinases. We found that ceramides are highly toxic to both cc-
RCC cell lines we tested. Ceramides are known to induce ER stress, resulting in the unfolded
protein response, as well as participate in autophagic response signaling [39]. We have previ-
ously shown that engerin A induced autophagy [22] in contrast to others [19,24] who did not
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observe autophagy in response to englerin A. However, in these studies, autophagy was likely
inhibited by the supplementation of the cell culture media with non-essential amino acids,
which is known to act as an inhibitor of autophagy [60]. In this study, we demonstrated that
englerin A induced ER stress at the molecular, cellular, and organelle level. Moreover, we
have previously found that englerin A inhibited Akt activation, another action common to
that of ceramides [22]. Collectively, our results indicate that ceramides and englerin A have
several actions in common. Adding to this list of shared activities, a recent study reported
that englerin A activated PKCθ, thereby inducing insulin resistance and inhibition of glucose
uptake [23]. It is well established that ceramides induce insulin resistance [61–63] as well as
inhibit glucose uptake [64]. Moreover, ceramides have been shown to activate the atypical
PKC isoform PKCz [65] and, like diacylglycerol (DAG), activate PKCθ in skeletal muscle
[66,67]. Hence, it is possible that englerin A may activate PKCθ via induction of ceramides
in addition to direct activation. Another well known activity of ceramides is the regulation of
intracellular calcium levels and modulation of calcium channels [68–70]. Englerin A has
been established to increase intracellular calcium levels [19] and this activity too may be
modulated by ceramides. Though ceramides inhibit the L-type calcium channels [68], as eng-
lerin A was recently reported to do [26], it is unlikely that ceramides mediate this effect of
englerin A. Modulation of L-type calcium channels by englerin A occurred at micromolar
levels (Ki = 5.7 μM) while ceramides accumulate significantly in cc-RCC cells at nanomolar
concentrations of englerin A. Ceramides were not found to modulate the TRPC4/5 channels
and thus do not mediate englerin A activation of TRPC4/5 channels [71]. However, our col-
lective results including the significant rise in ceramides in A498 cells in response to englerin
A, as well as the many activities that ceramides and englerin A have in common, suggest that
ceramides may mediate some of the actions of englerin A, especially in inducing ER stress,
autophagy, and inflammation.
Our results also indicated that englerin induced an inflammatory response that may in
part be due to ER stress. This inflammatory response was an acute inflammatory response
characterized by acute phase response signaling, activation of IRF by cytosolic pattern recog-
nition receptors, pathogen induced signaling, and a RIG-I/MDA5 mediated induction of
IFN-alpha/beta pathways as determined by Ingenuity and GeneSpring pathway analyses.
Though chronic inflammation may promote tumorigenesis, acute inflammation can result
in tumor regression. For instance, the agent Calmette-Guerin, an agent that induces an acute
inflammatory response [72], has been used for decades to induce tumor regression in blad-
der cancer patients. Moreover, in one study, the use of inflammatory agents including
polyinosinic:polycytidylic, Bacillus Calmette Guerin, Complete Freund’s adjuvant, and
Incomplete Freund’s Adjuvant induced anti-tumor activity in CD1 mice injected with Ehr-
lich ascites carcinoma [73]. The induction of an acute inflammatory response involving
interferon signaling is believed to allow priming of T-cells and infiltration of these cells into
tumors, thereby providing anti-tumor immunity. A very recent study has demonstrated this
concept by using synthetic cyclic dinucleotides to activate stimulator of interferon genes
(STING), a transmembrane protein localized to the ER that undergoes a conformational
change in response to direct binding of cyclic dinucleotides, resulting in a downstream sig-
naling cascade involving TBK1 activation, IRF-3 phosphorylation, and production of IFN-ß
and other cytokines [74]. Intratumoral injection of this STING activator induced regression
of established tumors and generated systemic immune responses, mediating rejection of dis-
tant metastases and providing immunologic memory. These findings suggest that englerin
A, by activating INF-α/ß signaling in addition to that of other inflammatory cytokines, likely
by ER stress, may prime T-cells in the tumor microenvironment to result in anti-tumor
immunity and tumor regression [75].
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Conclusion
Using a systems biology approach, the current study revealed for the first time that englerin A,
at nanomolar concentrations, profoundly disrupted lipid metabolism unique to cc-RCC and
generated ceramides that may mediate some of the effects of englerin A. Furthermore, our
study revealed that engerin A induced ER stress and an acute inflammatory response akin to
responses against pathogens. Importantly, these findings suggest that cc-RCC is highly sensi-
tive to disruptions in lipid metabolism and ER stress and that these vulnerabilities can be tar-
geted for the treatment of cc-RCC and possibly other lipid storing cancers. Lastly, the acute
inflammatory response induced by englerin A may mediate anti-tumor immunity.
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